Endothelial cell-by-cell profiling reveals the temporal dynamics of VEGFR1 and VEGFR2 membrane localization after murine hindlimb ischemia

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 304, Issue 8, 2013, Pages

  Imoukhuede, P I ^a   Dokun, Ayotunde O ^b   Annex, Brian H ^b   Popel, Aleksander S ^c  

^a University of Illinois at Urbana Champaign   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

^c Johns Hopkins University   (United States)

Author keywords

Angiogenesis; Endothelial cells; Hindlimb ischemia; Peripheral artery disease; Quantibrite; Quantitative flow cytometry; Receptor localization; Skeletal muscle; Vascular endothelial growth factor receptor

Indexed keywords

CD31 ANTIGEN; CD34 ANTIGEN; CYCLINE; MESSENGER RNA; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; FLT1 PROTEIN, MOUSE; UROKINASE; UROKINASE RECEPTOR;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTERY LIGATION; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; ENDOTHELIUM CELL; EX VIVO STUDY; FEMALE; FEMORAL ARTERY; HINDLIMB; HUMAN; LEG ISCHEMIA; MALE; MOLECULAR DYNAMICS; NONHUMAN; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SIGNAL TRANSDUCTION; SYSTEMS BIOLOGY; UPREGULATION; ANIMAL; C57BL MOUSE; CELL MOTION; DISEASE MODEL; FLOW CYTOMETRY; GENETICS; ISCHEMIA; LIGATION; METABOLISM; MOUSE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SKELETAL MUSCLE; TIME; VASCULARIZATION;

ANIMALS; CELL MOVEMENT; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; ENDOTHELIAL CELLS; FEMALE; FEMORAL ARTERY; FLOW CYTOMETRY; HINDLIMB; ISCHEMIA; LIGATION; MALE; MICE; MICE, INBRED C57BL; MUSCLE, SKELETAL; NEOVASCULARIZATION, PHYSIOLOGIC; PERIPHERAL ARTERIAL DISEASE; PROLIFERATING CELL NUCLEAR ANTIGEN; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TIME FACTORS; UP-REGULATION; UROKINASE-TYPE PLASMINOGEN ACTIVATOR; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

MLCS; MLOWN;

EID: 84878463418     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00514.2012     Document Type: Article

References (76)

1. Antonucci F, Cerri C, Vetencourt JFM, Caleo M. Acute neuroprotection by the synaptic blocker botulinum neurotoxin E in a rat model of focal cerebral ischaemia. Neuroscience 169: 395-401, 2010.
2. Attanasio S, Snell J. Therapeutic angiogenesis in the management of critical limb ischemia: current concepts and review. Cardiol Rev 17: 115-120, 2009.
3. Autiero M, Waltenberger J, Communi D, Kranz A, Moons L, Lambrechts D, Kroll J, Plaisance S, De Mol M, Bono F, Kliche S, Fellbrich G, Ballmer-Hofer K, Maglione D, Mayr-Beyrle U, Dewerchin M, Dombrowski S, Stanimirovic D, Van Hummelen P, Dehio C, Hicklin DJ, Persico G, Herbert JM, Communi D, Shibuya M, Collen D, Conway EM, Carmeliet P. Role of PlGF in the intra-and intermolecular cross talk between the VEGF receptors Flt1 and Flk1. Nat Med 9: 936-943, 2003.
4. Bailey AM, O'Neill TJ, Morris CE, Peirce SM. Arteriolar remodeling following ischemic injury extends from capillary to large arteriole in the microcirculation. Microcirculation 15: 389-404, 2008.
5. Balanda KP, MacGillivray HL. Kurtosis: a critical review. Am Stat 42: 111-119, 1988.
6. Barone FC, Knudsen DJ, Nelson AH, Feuerstein GZ, Willette RN. Mouse strain differences in susceptibility to cerebral ischemia are related to cerebral vascular anatomy. J Cereb Blood Flow Metab 13: 683-692, 1993.
7. Bauer AL, Jackson TL, Jiang Y. A cell-based model exhibiting branching and anastomosis during tumor-induced angiogenesis. Biophys J 92: 3105-3121, 2007.
8. Belch J, Hiatt WR, Baumgartner I, Driver IV, Nikol S, Norgren L, Van Belle E. Effect of fibroblast growth factor NV1FGF on amputation and death: a randomised placebo-controlled trial of gene therapy in critical limb ischaemia. Lancet 377: 1929-1937, 2011.
9. Berthaut A, Mirshahi P, Benabbou N, Azzazene D, Bordu C, Therwath A, Legeais JM, Mirshahi M. Vascular endothelial growth factor receptor-1 (VEGFR-1) expression in human corneal fibroblast decreased with age. Mol Vis 15: 1997-2007, 2009.
10. Bhattacharya R, Kang-Decker N, Hughes DA, Mukherjee P, Shah V, McNiven MA, Mukhopadhyay D. Regulatory role of dynamin-2 in VEGFR-2/KDR-mediated endothelial signaling. FASEB J 19: 1692-1694, 2005.
11. Binder B, Mihaly J, Prager G. uPAR-uPA-PAI-1 interactions and signaling: a vascular biologist's view. Thromb Haemost 97: 336-342, 2007.
12. Brogi E, Schatteman G, Wu T, Kim EA, Varticovski L, Keyt B, Isner JM. Hypoxia-induced paracrine regulation of vascular endothelial growth factor receptor expression. J Clin Invest 97: 469-476, 1996.
13. Cao F, Hata R, Zhu P, Niinobe M, Sakanaka M. Up-regulation of syntaxin1 in ischemic cortex after permanent focal ischemia in rats. Brain Res 1272: 52-61, 2009.
14. Celis JE, Celis A. Cell cycle-dependent variations in the distribution of the nuclear protein cyclin proliferating cell nuclear antigen in cultured cells: subdivision of S phase. Proc Natl Acad Sci USA 82: 3262-3266, 1985.
15. Chalothorn D, Clayton JA, Zhang H, Pomp D, Faber JE. Collateral density, remodeling, and VEGF-A expression differ widely between mouse strains. Physiol Genomics 30: 179-191, 2007.
16. Chen JH, Wang XC, Kan M, Sato JD. Effect of FGF-1 and FGF-2 on VEGF binding to human umbilical vein endothelial cells. Cell Biol Int 25: 257-260, 2001.
17. Chung AS, Ferrara N. Developmental and pathological angiogenesis. Annu Rev Cell Dev Biol 27: 563-584, 2011.
18. D'Agostino RB, Belanger A, D'Agostino RB Jr. A suggestion for using powerful and informative tests of normality. Am Stat 44: 316-321, 1990.
19. Dai Q, Huang J, Klitzman B, Dong C, Goldschmidt-Clermont PJ, March KL, Rokovich J, Johnstone B, Rebar EJ, Spratt SK, Case CC, Kontos CD, Annex BH. Engineered zinc finger-activating vascular endothelial growth factor transcription factor plasmid DNA induces therapeutic angiogenesis in rabbits with hindlimb ischemia. Circulation 110: 2467-2475, 2004.
20. Dokun AO, Keum S, Hazarika S, Li Y, Lamonte GM, Wheeler F, Marchuk DA, Annex BH. A quantitative trait locus (LSq-1) on mouse chromosome 7 is linked to the absence of tissue loss after surgical hindlimb ischemia. Circulation 117: 1207-1215, 2008.
21. Elowitz MB, Levine AJ, Siggia ED, Swain PS. Stochastic gene expression in a single cell. Science 297: 1183-1186, 2002.
22. Ewan LC, Jopling HM, Jia H, Mittar S, Bagherzadeh A, Howell GJ, Walker JH, Zachary IC, Ponnambalam S. Intrinsic tyrosine kinase activity is required for vascular endothelial growth factor receptor 2 ubiquitination, sorting and degradation in endothelial cells. Traffic 7: 1270-1282, 2006.
23. Finley S, Engel-Stefanini M, Imoukhuede PI, Popel A. Pharmacokinetics and pharmacodynamics of VEGF-neutralizing antibodies. BMC Sys Biol 5: 193, 2011.
24. Fong GH, Rossant J, Gertsenstein M, Breitman ML. Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature 376: 66-70, 1995.
25. Gampel A, Moss L, Jones MC, Brunton V, Norman JC, Mellor H. VEGF regulates the mobilization of VEGFR2/KDR from an intracellular endothelial storage compartment. Blood 108: 2624-2631, 2006.
26. Gerber HP, Condorelli F, Park J, Ferrara N. Differential transcriptional regulation of the two vascular endothelial growth factor receptor genes. J Biol Chem 272: 23659-23667, 1997.
27. Gevertz JL, Torquato S. Modeling the effects of vasculature evolution on early brain tumor growth. J Theor Biol 243: 517-531, 2006.
28. Ghajar CM, Kachgal S, Kniazeva E, Mori H, Costes SV, George SC, Putnam AJ. Mesenchymal cells stimulate capillary morphogenesis via distinct proteolytic mechanisms. Exp Cell Res 316: 813-825, 2010.
29. Gitay-Goren H, Soker S, Vlodavsky I, Neufeld G. The binding of vascular endothelial growth factor to its receptors is dependent on cell surface-associated heparin-like molecules. J Biol Chem 267: 6093-6098, 1992.
30. Gowdak LHW, Poliakova L, Wang X, Kovesdi I, Fishbein KW, Zacheo A, Palumbo R, Straino S, Emanueli C, Marrocco-Trischitta M, Lakatta EG, Anversa P, Spencer RGS, Talan M, Capogrossi MC. Adenovirus-mediated VEGF121 gene transfer stimulates angiogenesis in normoperfused skeletal muscle and preserves tissue perfusion after induction of ischemia. Circulation 102: 565-571, 2000.
31. Gupta R, Tongers J, Losordo DW. Human studies of angiogenic gene therapy. Circ Res 105: 724-736, 2009.
32. Hazarika S, Dokun AO, Li Y, Popel AS, Kontos CD, Annex BH. Impaired angiogenesis after hindlimb ischemia in type 2 diabetes mellitus: differential regulation of vascular endothelial growth factor receptor 1 and soluble vascular endothelial growth factor receptor 1. Circ Res 101: 948-956, 2007.
33. Helisch A, Wagner S, Khan N, Drinane M, Wolfram S, Heil M, Ziegelhoeffer T, Brandt U, Pearlman JD, Swartz HM, Schaper W. Impact of mouse strain differences in innate hindlimb collateral vasculature. Arterioscler Thromb Vasc Biol 26: 520-526, 2006.
34. Henry TD, Annex BH, McKendall GR, Azrin MA, Lopez JJ, Giordano FJ, Shah PK, Willerson JT, Benza RL, Berman DS, Gibson CM, Bajamonde A, Rundle AC, Fine J, McCluskey ER; VIVA investigators. The VIVA Trial: vascular endothelial growth factor in ischemia for vascular angiogenesis. Circulation 107: 1359-1365, 2003.
35. Hiratsuka S, Minowa O, Kuno J, Noda T, Shibuya M. Flt-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice. Proc Natl Acad Sci USA 95: 9349-9354, 1998.
36. Imoukhuede PI, Popel AS. Expression of VEGF receptors on endothelial cells in mouse skeletal muscle. PLoS One 7: e44791, 2012.
37. Imoukhuede PI, Popel AS. Quantification and cell-to-cell variation of vascular endothelial growth factor receptors. Exp Cell Res 317: 955-965, 2011.
38. Jin X, Ge X, Zhu Dl Yan C, Chu YF, Chen Wd Liu J, Gao Pj. Expression and function of vascular endothelial growth factor receptors (Flt-1 and Flk-1) in vascular adventitial fibroblasts. J Mol Cell Cardiol 43: 292-300, 2007.
39. Jones MC, Caswell PT, Moran-Jones K, Roberts M, Barry ST, Gampel A, Mellor H, Norman JC. VEGFR1 (Flt1) regulates Rab4 recycling to control fibronectin polymerization and endothelial vessel branching. Traffic 10: 754-766, 2009.
40. Jopling HM, Howell GJ, Gamper N, Ponnambalam S. The VEGFR2 receptor tyrosine kinase undergoes constitutive endosome-to-plasma membrane recycling. Biochem Biophys Res Commun 410: 170-176, 2011.
41. Kearney JB, Kappas NC, Ellerstrom C, DiPaola FW, Bautch VL. The VEGF receptor flt-1 (VEGFR-1) is a positive modulator of vascular sprout formation and branching morphogenesis. Blood 103: 4527-4535, 2004.
42. Kremer C, Breier G, Risau W, Plate KH. Up-regulation of flk-1/ vascular endothelial growth factor receptor 2 by its ligand in a cerebral slice culture system. Cancer Res 57: 3852-3859, 1997.
43. Kroon ME, Koolwijk P, van der Vecht B, van Hinsbergh VWM. Urokinase receptor expression on human microvascular endothelial cells is increased by hypoxia: implications for capillary-like tube formation in a fibrin matrix. Blood 96: 2775-2783, 2000.
44. Lampugnani MG, Orsenigo F, Gagliani MC, Tacchetti C, Dejana E. Vascular endothelial cadherin controls VEGFR-2 internalization and signaling from intracellular compartments. J Cell Biol 174: 593-604, 2006.
45. Li J, Brown LF, Hibberd MG, Grossman JD, Morgan JP, Simons M. VEGF, flk-1, and flt-1 expression in a rat myocardial infarction model of angiogenesis. Am J Physiol Heart Circ Physiol 270: H1803-H1811, 1996.
46. Li Y, Hazarika S, Xie D, Pippen AM, Kontos CD, Annex BH. In mice with type 2 diabetes, a vascular endothelial growth factor (VEGF)-activating transcription factor modulates VEGF signaling and induces therapeutic angiogenesis after hindlimb ischemia. Diabetes 56: 656-665, 2007.
47. Luo D, Luo Y, He Y, Zhang H, Zhang R, Li X, Dobrucki WL, Sinusas AJ, Sessa WC, Min W. Differential functions of tumor necrosis factor receptor 1 and 2 signaling in ischemia-mediated arteriogenesis and angiogenesis. Am J Pathol 169: 1886-1898, 2006.
48. Mac Gabhann F, Annex B, Popel A. Gene therapy from the perspective of systems biology. Curr Opin Mol Ther 12: 570-577, 2010.
49. Mac Gabhann F, Ji J, Popel A. Multi-scale computational models of pro-angiogenic treatments in peripheral arterial disease. Anna Biomed Eng 35: 982-994, 2007.
50. Mac Gabhann F, Peirce SM. Collateral capillary arterialization following arteriolar ligation in murine skeletal muscle. Microcirculation 17: 333-347, 2010.
51. Majid A, He YY, Gidday JM, Kaplan SS, Gonzales ER, Park TS, Fenstermacher JD, Wei L, Choi DW, Hsu CY. Differences in vulnerability to permanent focal cerebral ischemia among 3 common mouse strains. Stroke 31: 2707-2714, 2000.
52. McClung J, McCord T, Keum S, Johnson S, Annex B, Marchuk D, Kontos C. Skeletal muscle-specific genetic determinants contribute to the differential strain-dependent effects of hindlimb ischemia in mice. Am J Pathol 180: 2156-2169, 2012.
53. Mittar S, Ulyatt C, Howell GJ, Bruns AF, Zachary I, Walker JH, Ponnambalam S. VEGFR1 receptor tyrosine kinase localization to the Golgi apparatus is calcium-dependent. Exp Cell Res 315: 877-889, 2009.
54. Morello JP, Plamondon J, Meyrick B, Hoover R, O'Connor-McCourt MD. Transforming growth factor-receptor expression on endothelial cells: heterogeneity of type III receptor expression. J Cell Physiol 165: 201-211, 1995.
55. Nielsen JS, McNagny KM. CD34 is a key regulator of hematopoietic stem cell trafficking to bone marrow and mast cell progenitor trafficking in the periphery. Microcirculation 16: 487-496, 2009.
56. Niepel M, Spencer SL, Sorger PK. Non-genetic cell-to-cell variability and the consequences for pharmacology. Curr Opin Chem Biol 13: 556-561, 2009.
57. Nilsson I, Shibuya M, Wennström S. Differential activation of vascular genes by hypoxia in primary endothelial cells. Exp Cell Res 299: 476-485, 2004.
58. Peirce SM. Computational and mathematical modeling of angiogenesis. Microcirculation 15: 739-751, 2008.
59. Pelkmans L. Using cell-to-cell variability-a new era in molecular biology. Science 336: 425-426, 2012.
60. Pepper MS, Sappino AP, Stocklin R, Montesano R, Orci L, Vassalli JD. Upregulation of urokinase receptor expression on migrating endothelial cells. J Cell Biol 122: 673-684, 1993.
61. Raj A, van Oudenaarden A. Nature, nurture, or chance: stochastic gene expression and its consequences. Cell 135: 216-226, 2008.
62. Rose NL, Palcic MM, Shapiro AMJ, Lakey JR. An evaluation of the activation of endogenous pancreatic enzymes during human islet isolations. Transplant Proc 35: 2455-2457, 2003.
63. Rush JS, Quinalty LM, Engelman L, Sherry DM, Ceresa BP. Endosomal accumulation of the activated epidermal growth factor receptor (EGFR) induces apoptosis. J Biol Chem 287: 712-722, 2012.
64. Sawano A, Iwai S, Sakurai Y, Ito M, Shitara K, Nakahata T, Shibuya M. Flt-1, vascular endothelial growth factor receptor 1, is a novel cell surface marker for the lineage of monocyte-macrophages in humans. Blood 97: 785-791, 2001.
65. Shalaby F, Rossant J, Yamaguchi TP, Gertsenstein M, Wu XF, Breitman ML, Schuh AC. Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature 376: 62-66, 1995.
66. Sorkin A, von Zastrow M. Endocytosis and signalling: intertwining molecular networks. Nat Rev Mol Cell Biol 10: 609-622, 2009.
67. Stefanini MO, Wu FT, Mac Gabhann F, Popel AS. Increase of plasma VEGF after intravenous administration of bevacizumab is predicted by a pharmacokinetic model. Cancer Res 70: 9886-9894, 2010.
68. Takeshita S, Pu LQ, Stein LA, Sniderman AD, Bunting S, Ferrara N, Isner JM, Symes JF. Intramuscular administration of vascular endothelial growth factor induces dose-dependent collateral artery augmentation in a rabbit model of chronic limb ischemia. Circulation 90: 228-234, 1994.
69. Tuder RM, Flook BE, Voelkel NF. Increased gene expression for VEGF and the VEGF receptors KDR/Flk and Flt in lungs exposed to acute or to chronic hypoxia. Modulation of gene expression by nitric oxide. J Clin Invest 95: 1798-1807, 1995.
70. Tuomisto TT, Rissanen TT, Vajanto I, Korkeela A, Rutanen J, Ylä-Herttuala S. HIF-VEGF-VEGFR-2, TNF-α and IGF pathways are upregulated in critical human skeletal muscle ischemia as studied with DNA array. Atherosclerosis 174: 111-120, 2004.
71. Uchida C, Haas TL. Evolving strategies in manipulating VEGF/VEGFR signaling for the promotion of angiogenesis in ischemic muscle. Curr Pharm Des 15: 411-421, 2009.
72. Waltenberger J, Claesson-Welsh L, Siegbahn A, Shibuya M, Heldin CH. Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor. J Biol Chem 269: 26988-26995, 1994.
73. Waltenberger J, Mayr U, Pentz S, Hombach V. Functional upregulation of the vascular endothelial growth factor receptor KDR by hypoxia. Circulation 94: 1647-1654, 1996.
74. Willmann JK, Chen K, Wang H, Paulmurugan R, Rollins M, Cai W, Wang DS, Chen IY, Gheysens O, Rodriguez-Porcel M, Chen X, Gambhir SS. Monitoring of the biological response to murine hindlimb ischemia with 64Cu-labeled vascular endothelial growth factor-121 positron emission tomography. Circulation 117: 915-922, 2008.
75. Wu FTH, Stefanini MO, Gabhann FM, Kontos CD, Annex BH, Popel AS. VEGF and soluble VEGF receptor-1 (sFlt-1) distributions in peripheral arterial disease: an in silico model. Am J Physiol Heart Circ Physiol 298: H2174-H2191, 2010.
76. Zhang Z, Neiva K, Lingen M, Ellis L, Nor J. VEGF-dependent tumor angiogenesis requires inverse and reciprocal regulation of VEGFR1 and VEGFR2. Cell Death Differ 17: 499-512, 2010.